Gongwin Biopharm Holdings (6617) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 共信-KY

Gongwin Biopharm Holdings (6617) reported revenue of NT$9.3 million for Oct 2026, +397.3% year on year and +221.7% from the previous month. Revenue for Jan–Oct 2026 was NT$43.2 million (+42.2% year on year).

Revenue for Oct 2026 was a record high (previous high: Sep 2025, NT$5.1 million). →

In Oct 2026, it ranked No. 136 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$2.7 million24/10Nov 2024 NT$3 millionDec 2024 NT$2.7 millionJan 2025 NT$2.4 millionFeb 2025 NT$2.4 million25/02Mar 2025 NT$2.8 millionApr 2025 NT$3.5 millionMay 2025 NT$2.6 millionJun 2025 NT$2.7 million25/06Jul 2025 NT$2.8 millionAug 2025 NT$4.3 millionSep 2025 NT$5.1 millionOct 2025 NT$1.9 million25/10Nov 2025 NT$2.6 millionDec 2025 NT$3.5 millionJan 2026 NT$3.2 millionFeb 2026 NT$2.8 million26/02Mar 2026 NT$3.1 millionApr 2026 NT$3.8 millionMay 2026 NT$4.4 millionJun 2026 NT$4.5 million26/06Jul 2026 NT$4.6 millionAug 2026 NT$4.6 millionSep 2026 NT$2.9 millionOct 2026 NT$9.3 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$9.3 million+397.3%+221.7%
Sep 2026NT$2.9 million-42.6%-37.7%
Aug 2026NT$4.6 million+7.8%+1.3%
Jul 2026NT$4.6 million+63.5%+1.8%
Jun 2026NT$4.5 million+70.0%+1.8%
May 2026NT$4.4 million+68.5%+18.0%
Apr 2026NT$3.8 million+7.6%+21.2%
Mar 2026NT$3.1 million+11.1%+11.5%
Feb 2026NT$2.8 million+13.4%-14.4%
Jan 2026NT$3.2 million+36.2%-7.5%
Dec 2025NT$3.5 million+30.5%+35.3%
Nov 2025NT$2.6 million-12.5%+38.3%
Oct 2025NT$1.9 million-31.5%-62.9%
Sep 2025NT$5.1 million+82.2%+17.2%
Aug 2025NT$4.3 million+35.7%+53.7%
Jul 2025NT$2.8 million+1.5%+5.8%
Jun 2025NT$2.7 million-29.2%+0.9%
May 2025NT$2.6 million-25.6%-24.6%
Apr 2025NT$3.5 million+41.8%+25.2%
Mar 2025NT$2.8 million+18.7%+13.8%
Feb 2025NT$2.4 million+69.9%+2.8%
Jan 2025NT$2.4 million+40.0%-11.4%
Dec 2024NT$2.7 million-30.7%-9.3%
Nov 2024NT$3 million+36.9%+8.3%
Oct 2024NT$2.7 million+4.8%-1.3%

Jan–Oct 2026 cumulative: NT$43.2 million (+42.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Gongwin Biopharm Holdings vs PEC / Gongwin Biopharm Holdings vs Lotus Pharm / Gongwin Biopharm Holdings vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

自2018年度起依據國際會計準則公報15號規定認列收入

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16